北交所上市国产仪器公司被问询，亲属企业业务重合引关注

Core Viewpoint - The article discusses the second round of inquiry by the Beijing Stock Exchange regarding the IPO of Shandong Kanghua Biomedical Technology Co., Ltd., focusing on key operational risks and issues related to the company's business practices and financial management [1]. Group 1: Inquiry Focus Areas - The inquiry highlights six main areas of concern, including post-IPO performance decline risk, adequacy of distributor management and cash flow verification, reasonableness of large inventory impairment provisions, related party transactions with companies controlled by the actual controller's relatives, and the necessity and rationality of fundraising projects [1]. - The actual controllers of Kanghua, Yang Zhiting, Wang Aixiang, and Yang Fan, collectively hold 90.07% of the shares, indicating a high concentration of ownership [2]. Group 2: Related Party Transactions - The inquiry emphasizes potential competition and related party transactions involving seven companies controlled by Yang Zhiting's brother and son, which operate in similar fields as Kanghua, leading to overlapping sales regions and shared suppliers and customers [2]. - The report indicates that there are 18 overlapping suppliers and 6 overlapping customers between Kanghua and the seven companies, raising concerns about the nature of these relationships [2]. Group 3: Financial and Operational Analysis - The Beijing Stock Exchange requests detailed explanations regarding the revenue, profit, and sales figures related to overlapping customers and suppliers, as well as the fairness of pricing in transactions between Kanghua and the related companies [3]. - The inquiry also seeks clarification on whether there are any plans for Kanghua to acquire the related companies and the nature of financial transactions between them, assessing the potential for profit transfer [3].